BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11472206)

  • 1. Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Hatzelmann A; Van Klink GP; Van der Laan IJ; Sterk GJ; Thibaut U; Ulrich WR; Timmerman H
    J Med Chem; 2001 Aug; 44(16):2523-35. PubMed ID: 11472206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Boss H; Couwenberg D; Hatzelmann A; Sterk GJ; Goubitz K; Schenk H; Timmerman H
    J Med Chem; 2002 Jun; 45(12):2526-33. PubMed ID: 12036361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.
    Van der Mey M; Hatzelmann A; Van der Laan IJ; Sterk GJ; Thibaut U; Timmerman H
    J Med Chem; 2001 Aug; 44(16):2511-22. PubMed ID: 11472205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Boss H; Hatzelmann A; Van der Laan IJ; Sterk GJ; Timmerman H
    J Med Chem; 2002 Jun; 45(12):2520-5. PubMed ID: 12036360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.
    Van der Mey M; Bommelé KM; Boss H; Hatzelmann A; Van Slingerland M; Sterk GJ; Timmerman H
    J Med Chem; 2003 May; 46(10):2008-16. PubMed ID: 12723963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.
    Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
    Bioorg Med Chem Lett; 2001 Jan; 11(1):33-7. PubMed ID: 11140727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.
    Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Fattori R; Ferlenga P; Pradella L
    Bioorg Med Chem Lett; 2002 Jan; 12(1):5-8. PubMed ID: 11738561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.
    Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
    Bioorg Med Chem Lett; 2000 Oct; 10(19):2235-8. PubMed ID: 11012037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and potential anti-inflammatory activity of some tetrahydrophthalazinones.
    Gouault N; Pinel B; Cupif JF; Depince A; Martin-Chouly CA; Belleguic C; David M
    J Enzyme Inhib Med Chem; 2004 Dec; 19(6):475-80. PubMed ID: 15662951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
    Ukita T; Sugahara M; Terakawa Y; Kuroda T; Wada K; Nakata A; Ohmachi Y; Kikkawa H; Ikezawa K; Naito K
    J Med Chem; 1999 Mar; 42(6):1088-99. PubMed ID: 10090791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors.
    Giovannoni MP; Cesari N; Graziano A; Vergelli C; Biancalani C; Biagini P; Dal Piaz V
    J Enzyme Inhib Med Chem; 2007 Jun; 22(3):309-18. PubMed ID: 17674813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors.
    Pascal Y; Andrianjara CR; Auclair E; Avenel N; Bertin B; Calvet A; Féru F; Lardon S; Moodley I; Ouagued M; Payne A; Pruniaux MP; Szilagyi C
    Bioorg Med Chem Lett; 2000 Jan; 10(1):35-8. PubMed ID: 10636238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors.
    Barnes MJ; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Galvin FC; Gowers L; Haughan AF; Lowe C; Meissner JW; Montana JG; Morgan T; Picken CL; Watson RJ
    Bioorg Med Chem Lett; 2001 Apr; 11(8):1081-3. PubMed ID: 11327595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2,1,3-Benzothiadiazine derivatives: synthesis and screening versus PDE4 enzyme.
    Tait A; Luppi A; Avallone R; Baraldi M
    Farmaco; 2005 Aug; 60(8):653-63. PubMed ID: 15963514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 4 isoenzyme inhibitory activity of 3-phenylxanthines and 4-pheny.
    Suzuki H; Sawanishi H; Yamamoto K; Yokogawa K; Miyamoto K
    Chem Pharm Bull (Tokyo); 2001 Feb; 49(2):188-91. PubMed ID: 11217107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationship of N-arylrolipram derivatives as inhibitors of PDE4 isozymes.
    Keller TH; Bray-French K; Demnitz FW; Müller T; Pombo-Villar E; Walker C
    Chem Pharm Bull (Tokyo); 2001 Aug; 49(8):1009-17. PubMed ID: 11515569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical asymmetric synthesis of a potent PDE4 inhibitor via stereoselective enolate alkylation of a chiral aryl-heteroaryl secondary tosylate.
    O'Shea PD; Chen CY; Chen W; Dagneau P; Frey LF; Grabowski EJ; Marcantonio KM; Reamer RA; Tan L; Tillyer RD; Roy A; Wang X; Zhao D
    J Org Chem; 2005 Apr; 70(8):3021-30. PubMed ID: 15822960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
    Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
    J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.
    MacKenzie SJ; Houslay MD
    Biochem J; 2000 Apr; 347(Pt 2):571-8. PubMed ID: 10749688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
    Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
    Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.